Volume 27, Number 5—May 2021
Research
Symptom Diary–Based Analysis of Disease Course among Patients with Mild Coronavirus Disease, Germany, 2020
Patricia Nicole Wiegele1, Iyad Kabar1, Laura Kerschke, Christopher Froemmel, Anna Hüsing-Kabar, Hartmut Schmidt, Elena Vorona, Richard Vollenberg, and Phil-Robin Tepasse
Table 1
COVID-19 symptom characteristics in 313 patients participating in a symptom diary–based analysis of COVID-19 disease course, Germany, 2020*
| Symptom | Prevalence, no. (%)† | Median day of onset (minimum–maximum)‡ |
|---|---|---|
| Fatigue | 285 (91.1) | 1.0 (1–18) |
| Cough | 266 (85.0) | 1.0 (1–15) |
| Headache | 244 (78.0) | 1.0 (1–13) |
| Myalgia | 229 (73.2) | 1.0 (1–18) |
| Rhinitis | 220 (70.3) | 1.0 (1–20) |
| Loss of taste | 208 (66.5) | 4.0 (1–19) |
| Sore throat | 204 (65.2) | 1.0 (1–10) |
| Loss of smell | 195 (62.3) | 3.0 (1–19) |
| Fever | 191 (61.0) | 2.0 (1–20) |
| Dysgeusia | 162 (51.8) | 4.0 (1–2) |
| Dyspnea | 160 (51.1) | 3.0 (1–15) |
| Loss of appetite | 140 (44.7) | 3.0 (1–13) |
| Dizziness | 126 (40.3) | 2.0 (1–20) |
| Diarrhea | 102 (32.6) | 4.0 (1–20) |
| Nausea | 100 (31.9) | 3.0 (1–20) |
| Abdominal pain | 88 (28.1) | 2.5 (1–20) |
| Hearing loss | 62 (19.8) | 3.0 (1–16) |
| Vision disorders | 58 (18.5) | 3.0 (1–20) |
| Mucosal lesions | 43 (13.7) | 2.0 (1–12) |
| Skin lesions | 31 (9.9) | 6.0 (1–13) |
| Vomiting | 10 (3.2) | 5.0 (1–11) |
*COVID-19, coronavirus disease. †Symptom occurrence within the observation period was based on the overall cohort. Results shown as absolute and relative frequencies. †Day of symptom onset. Calculations of median days to symptom onset were restricted to patients who reported experiencing that symptom.
1These authors contributed equally to this article.
Page created: February 25, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.